Federated Hermes
ABCL icon

Federated Hermes’s AbCellera Biologics ABCL Stock Holding History

Federated Hermes’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,141
Closed -$15.8K – 2065
2025
Q3 		$15.8K Sell
3,141
-49,859
-94% -$220K ﹤0.01% 1834
2025
Q2 		$182K Sell
53,000
-894,751
-94% -$2.23M ﹤0.01% 1510
2025
Q1 		$2.11M Buy
947,751
+31,514
+3% +$90.4K ﹤0.01% 919
2024
Q4 		$2.68M Sell
916,237
-1,366,459
-60% -$3.81M 0.01% 866
2024
Q3 		$5.94M Sell
2,282,696
-443,320
-16% -$1.23M 0.01% 685
2024
Q2 		$8.07M Sell
2,726,016
-89,443
-3% -$338K 0.02% 599
2024
Q1 		$12.8M Sell
2,815,459
-302,221
-10% -$1.54M 0.03% 521
2023
Q4 		$17.8M Sell
3,117,680
-136,673
-4% -$633K 0.04% 417
2023
Q3 		$15M Sell
3,254,353
-119,702
-4% -$728K 0.04% 437
2023
Q2 		$21.8M Buy
3,374,055
+469,796
+16% +$3.21M 0.05% 359
2023
Q1 		$21.9M Buy
2,904,259
+381,937
+15% +$3.47M 0.06% 368
2022
Q4 		$25.6M Buy
2,522,322
+418,281
+20% +$4.83M 0.07% 327
2022
Q3 		$20.8M Buy
2,104,041
+367,822
+21% +$4.04M 0.06% 372
2022
Q2 		$18.5M Buy
1,736,219
+448,219
+35% +$3.8M 0.05% 405
2022
Q1 		$12.6M Buy
1,288,000
+460,153
+56% +$4.36M 0.03% 547
2021
Q4 		$11.8M Buy
827,847
+237,847
+40% +$3.61M 0.02% 603
2021
Q3 		$11.8M Buy
590,000
+194,000
+49% +$3.43M 0.02% 604
2021
Q2 		$8.71M Buy
396,000
+346,000
+692% +$9.54M 0.02% 704
2021
Q1 		$1.7M Hold
50,000
– – ﹤0.01% 1164
2020
Q4 		$2.01M Buy
+50,000
New +$2.29M ﹤0.01% 1062

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes's ABCL Position: Q4 2025 in Review

Federated Hermes sold out of AbCellera Biologics (ABCL) in Q4 2025, closing a stake of 3,141 shares — an estimated $15.8K sold.

Federated Hermes first reported a position in ABCL in Q4 2020 and held it in 20 quarters. The position peaked at $25.6M in Q4 2022. 144 funds tracked by Wall St. Rank hold ABCL as of Q4 2025.

  • Federated Hermes reported no remaining AbCellera Biologics position as of Q4 2025 after selling out during the quarter.
  • Federated Hermes sold 3,141 AbCellera Biologics shares in Q4 2025, an estimated $15.8K.
  • Federated Hermes first reported a position in AbCellera Biologics in Q4 2020 and held it in 20 quarters.
  • Federated Hermes's AbCellera Biologics position peaked at $25.6M in Q4 2022.
  • 144 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2025.

Based on Federated Hermes's 13F filing for Q4 2025, filed 12 Feb 2026.